Semler Dirty Data: EMA Suspends Over 200 Products; Stings Indian CROs
Dirty data issues continue to plague Indian contract research organizations, denting the reputation of the beleaguered local industry and piling up challenges for marketing authorization holders. The European Medicines Agency (EMA) has now suspended close to 300 products that relied on flawed bioequivalence studies done by the Bengaluru-based Semler Research.
You may also be interested in...
Gene therapy should remain on the market, FDA says, but Novartis could face civil or criminal penalties. Firm knew of problems before approval.
A top FDA compliance official warns the generic drug industry of a “revival” of data integrity fraud as a number of brand-name drugs go off patent and companies rush to be the first to file.
Data integrity concerns continue to cloud outlook for India’s contract research sector. The European Medicines Agency’s latest action against Micro Therapeutic Research Labs suspends more than 300 products in the EU over “unreliable” data and the firm tells Pink Sheet this will result in a “considerable dent” in its operations.